Viatris to settle EpiPen antitrust litigation for $264 million
28/2 12:03
Viatris Inc, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment. (Reporting by Nate Raymond in Boston; Editing by Aditya Soni) (([email protected] and Twitter @nateraymond; 347-243-6917; Reuters Messaging: [email protected])) nL4N2V33KK...